论文部分内容阅读
目的:观察EB病毒(EBV)潜伏膜蛋白1(LMP1)抗体在鼻咽癌(NPC)患者血清中的水平,探讨LMP1抗体检测在NPC血清学诊断、预后判断及肿瘤靶向免疫治疗中的临床意义。方法:采用ELISA及West-ern blot方法,以LMP1融合蛋白检测61例NPC患者(NPC组)、30例鼻咽炎患者(鼻咽炎组)和55例正常人(对照组)血清中LMP1抗体水平。分析LMP1抗体水平与NPC临床病理特征的关系。结果:ELISA方法证实,NPC组LMP1抗体水平明显高于鼻咽炎组及对照组,鼻咽炎组LMP1抗体水平明显高于对照组,组间均差异有统计学意义(均P<0.05)。NPC组LMP1抗体水平在NPC不同病理分级及有无淋巴结转移中均差异无统计学意义(均P>0.05)。Western blot方法表明,NPC组LMP1抗体的表达均较鼻咽炎组及对照组高。结论:NPC组EBV LMP1抗体水平显著高于鼻咽炎组及对照组,LMP1融合蛋白可考虑作为肿瘤抗原标志物辅助NPC血清学诊断及肿瘤靶向免疫治疗。
OBJECTIVE: To observe the levels of Epstein-Barr virus (EBV) LMP1 antibody in the serum of patients with nasopharyngeal carcinoma (NPC) and to investigate the clinical application of LMP1 antibody in the diagnosis of NPC, prognosis and tumor-targeted immunotherapy significance. Methods: The levels of LMP1 antibody in serum of 61 patients with NPC (NPC group), 30 patients with nasopharyngitis (nasopharyngitis) and 55 normal controls (control group) were detected by ELISA and West-ern blot using LMP1 fusion protein. The relationship between LMP1 antibody level and clinicopathological features of NPC was analyzed. Results: ELISA demonstrated that the level of LMP1 antibody in NPC group was significantly higher than that in nasopharyngitis group and control group. The level of LMP1 antibody in nasopharyngitis group was significantly higher than that in control group (all P <0.05). There was no significant difference in the levels of LMP1 antibody in NPC between different pathological grades of NPC and lymph node metastasis (all P> 0.05). Western blot showed that the expression of LMP1 antibody in NPC group was higher than that in nasopharyngitis group and control group. CONCLUSION: The level of EBV LMP1 antibody in NPC group is significantly higher than that in nasopharyngitis group and control group. LMP1 fusion protein can be considered as a tumor antigen marker to aid in the diagnosis of NPC and tumor-targeted immunotherapy.